[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594418":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":11,"centralContacts":30,"locations":11,"responsibleParty":37,"collaborators":11,"id":39,"slug":11,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":11,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":11,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":11,"overallStatus":57,"whyStopped":11,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":11},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tislelizumab combined with chemotherapy","EXPERIMENTAL",null,[13,14,15],"Drug: Tislelizumab","Drug: albumin-bound paclitaxel","Drug: Nedaplatin",[17,22,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":11},"DRUG","Tislelizumab","Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks",[9],{"type":18,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"albumin-bound paclitaxel","albumin-bound paclitaxel 260mg\u002Fm2，day 1 of every 3 weeks",[9],{"type":18,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"Nedaplatin","Nedaplatin 80mg\u002Fm2，day 1 of every 3 weeks",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Geng guo jun, Doctor","CONTACT","13365922380","86","ggj622@126.com",{"type":38,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100594418",false,"NCT07019181","Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma","Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma： Single-arm Clinical Phase II Study","Inclusion Criteria:\n\n* Subjects were enrolled in the study and signed an informed consent form.\n* Male or female patients between the ages of 18 and 75.\n* Patients with esophageal squamous carcinoma diagnosed by histopathology.\n* According to the TNM staging system of esophageal cancer in the 8th edition of the AJCC,the disease is in the stage of cT3-4aN0M0 or cT1b-4aN+M0 (confirmed by thoracic and abdominal enhancement CT\u002FMRI), and the lesion is located in the thoracic segment.\n* ECOG score: 0-1.\n* Normal functioning of major organs, i.e. meeting the following criteria.\n\n  1. Blood count (no blood transfusions, granulocyte colony-stimulating factor \\[G-CSF\\], or other medications corrected within 14 days prior to treatment); and Absolute neutrophil count (ANC) ≥1.5×109\u002FL; hemoglobin (HB) ≥9.0 g\u002FdL; and Platelet count (PLT) ≥ 100 x 109\u002FL;\n  2. blood biochemistry Creatinine clearance ≥60 mL\u002Fmin. Total bilirubin (TBIL) ≤ 1.5 x ULN. Albuminous aminotransferase (AST) or albuminous aminotransferase (ALT) levels ≤ 2.5 x ULN;\n* Expected survival \\> 6 months.\n* Female subjects of childbearing potential and male subjects with partners of childbearing potential are required to use a medically approved contraceptive method during study treatment and for at least 6 months after the last treatment.\n\nExclusion Criteria:\n\n* The presence of clinically uncontrolled chest that required repeated drainage or medical intervention (within 2 weeks prior to randomization) Hydrocele, pericardial hydrocele or ascites;\n* Known intolerance or resistance to chemotherapy specified in the trial protocol;\n* Have received any other ESCC anti-tumor therapy (e.g., targeting PD-1, PD-L1, PD-L2) Or other tumor immunotherapy, radiotherapy, targeted therapy, ablation, or other systemic or local anti-tumor therapy);\n* Patients who have an active autoimmune disease or have a history of an autoimmune disease but may relapse may have a known abnormality History of body organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* A history of interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic disease, including pulmonary fibrosis, Acute lung disease;\n* There were severe chronic or active patients requiring systemic antimicrobial therapy, antifungal therapy or antiviral therapy before enrollment Infection (including tuberculosis infection, etc.);\n* Have a known history of HIV infection;\n* The presence of any serious or uncontrolled systemic disease, including but not limited to:\n\nUnstable angina pectoris, congestive heart failure, New York Heart Association (NYHA) grade ≥ 2 chronic heart failure; Any arterial thrombosis, embolism, or ischemia, such as myocardial infarction, cerebrovascular accident, or transient ischemic attack, during the 6 months prior to the first dose of the study; Uncontrolled hypertension (i.e., ≥ CTC-AE level 2 hypertension after medication); active pulmonary tuberculosis; those who have a history of psychotropic substance abuse and cannot abstain or have mental disorders;\n\n* Had other malignancies in the past 5 years (cured skin basal cell carcinoma, breast carcinoma in situ and Except primary cervical cancer);\n* Had received live vaccine within 28 days prior to enrollment;\n* Have participated in other therapeutic clinical trials within 4 weeks;\n* And those deemed unsuitable for inclusion by the researchers.","ALL","18 Years","75 Years",{"count":49,"type":50},26,"ESTIMATED","INTERVENTIONAL",[53],"PHASE2","Evaluating the rate of pathologic complete remission in patients with squamous esophageal cancer treated perioperatively with tislelizumab in combination with chemotherapy",[56],"Esophagus Cancer","NOT_YET_RECRUITING","2025-06-12",{"date":60,"type":61},"2025-06-13","ACTUAL",{"date":63,"type":50},"2025-07-30",{"date":65,"type":50},"2026-12-31",{"name":5,"class":6}]